The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci

Vaccine

Volumn 17, Issue 20-21, 1999, Pages 2677-2689

  Toropainen, Maija ^a   Käyhty, Helena ^a   Saarinen, Leena ^a   Rosenqvist, Einar ^b   Høiby, E Arne ^b   Wedege, Elisabeth ^b   Michaelsen, Terje ^b   Mäkelä, Pirjo Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Infant rat infection model; Neisseria meningitidis; Outer membrane protein vaccines

Indexed keywords

MEMBRANE ANTIGEN; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL COUNT; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNITY; INFECTION SENSITIVITY; MENINGITIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; RAT; SERUM;

ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; BACTEREMIA; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PHAGOCYTOSIS; RATS; RATS, WISTAR;

EID: 0033523063     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00049-3     Document Type: Article

References (45)

1. Steven N., Wood M. The clinical spectrum of meningococcal disease. Cartwright K., Meningococcal disease. 1995;177-205 John Wiley and Sons Ltd, Chichester, UK.
2. Peltola H. Meningococcal disease: still with us. Rev. Infect. Dis. 5:1983;71.
3. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1969;1327.
4. Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 282:1970;417.
5. Wahdan M.H., Rizk F., El-Akkad A.M., El Ghoroyry A.A., Hablas R., Girgis N.I., Amer A., Boctar W., Sippel J.E., Gotschlich E.C., Triau R., Sanborn W.R., Cvjetanoviċ B. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull. World Health Organ. 48:1973;667.
6. Frasch C.E., Coetzee G., Zahradnik J.M., Feldman H.A., Koornhof H.J. Development and evaluation of group B serotype 2 protein vaccines: report of a group B field trial. Med. Trop. 43:1983;177.
7. Mäkelä P.H., Käyhty H., Weckström P., Sivonen A., Renkonen O.-V. Effect of group A meningococcal vaccine in army recruits in Finland. Lancet. ii:1975;883.
8. Käyhty H., Karanko V., Peltola H., Sarna S., Mäkelä P.H. Serum antibodies to capsular polysaccharide vaccine of group A followed for three years in infants and children. J. Infect. Dis. 142:1980;868.
9. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., Berman S.L., Lowenthal J.P. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:1972;514.
10. Bjune G., Høiby E.A., Grønnesby J.K., Arnesen Ø., Fredriksen J.H., Halstensen A., Holten E., Lindbak A.-K., Nøkleby H., Rosenqvist E., Solberg L.K., Closs O., Eng J., Frøholm L.O., Lystad A., Bakketeig L.S., Hareide B. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 338:1991;1093.
11. Sierra G.V.G., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., Casanueva G.V., Rico C.O., Rodriguez C.R., Terry M.H. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH An. 14:1991;195.
12. the Chilean National Committee for Meningococcal Disease , Zollinger W.D., Boslego J., Moran E., Garcia J., Cruz C., Ruiz S., Brandt B., Martinez M., Arthur J., Underwood P., Hankins W., Mays J., Gilly J. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. NIPH An. 14:1991;211.
13. de Moraes J.C., Perkins B.A., Camargo M.C.C., Hidalgo N.T.R., Barbosa H.A., Sacchi C.T., Gral I.M.L., Gattas V.L., Vasconcelos H. de G., Plikaytis B.D., Wenger J.D., Broome C.V. Protective efficacy of a serogroup B meningococcal vaccine in São Paolo. Brazil. Lancet. 340:1992;1074.
14. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Høiby E.A., Rosenqvist E., Holst J., Nøkleby H., Sotolongo F., Sierra G., Campa H.C., Carlone G.M., Williams D., Dykes J., Kapczynski D., Tikhomirov E., Wenger J.D., Broome C.V. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:1998;683.
15. Roberts R.B. The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man. J. Exp. Med. 131:1970;499.
16. Ross S.C., Rosenthal P.J., Berberich H.M., Densen P. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis. 155:1987;1266.
17. Sjursen H., Lehmann V., Næss A., Hervig T., Flø R.W., Mæhle B., Halstensen A.I., Frøholm L.O. Monocyte phagocytosis of opsonized Neisseria meningitidis serogroup B. APMIS. 100:1992;209.
18. Aase A., Bjune G., Høiby E.A., Rosenqvist E., Pedersen A.K., Michaelsen T.E. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 63:1995;3531.
19. Smith H. Pathogenicity and the microbe in vivo. J. Gen. Microbiol. 136:1990;377.
20. Miller C.P. Experimental meningococcal infection in mice. Science. 78:1933;340.
21. Holbein B.E., Jericho K.W.F., Likes G.C. Neisseria meningitidis infection in mice: influence of iron, variations in virulence among strains and pathology. Infect. Immun. 24:1979;545.
22. Huet M., Suire A. Un modèle animal pour l'activité des vaccins polyosidiques méningococciques. J. Biol. Stand. 9:1981;67.
23. Salit I.E., Van Melle E., Tomalty L. Experimental meningococcal infection in neonatal animals: models for mucosal invasiveness. Can. J. Microbiol. 30:1984;1022.
24. Mackinnon F.G., Gorringe A.R., Funnell S.G.P., Robinson A. Intranasal infection of infant mice with Neisseria meningitidis. Microb. Pathog. 12:1992;415.
25. Saukkonen K. Experimental meningococcal meningitis in the infant rat. Microb. Pathog. 4:1988;203.
26. Saukkonen K., Abdillahi H., Poolman J.T., Leinonen M. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development. Microb. Pathog. 3:1987;261.
27. Saukkonen K., Leinonen M., Abdillahi H., Poolman J.T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine. 7:1989;325.
28. Nurminen M., Butcher S., Idänpään-Heikkilä I., Wahlström E., Muttilainen S., Runeberg-Nyman K., Sarvas M., Mäkelä P.H. The class 1 outer membrane protein of Neisseria meningitidis produced in Bacillus subtilis can give rise to protective immunity. Mol. Microbiol. 6:1992;2499.
29. Idänpään-Heikkilä I., Muttilainen S., Wahlström E., Saarinen L., Leinonen M., Sarvas M., Mäkelä P.H. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. Vaccine. 13:1995;1501.
30. Käyhty H., Poolman J.T., Abdillahi H., Sivonen A., Eskola J., Tarkka E., Peltola H. Sero- and subtypes of group B meningococci causing invasive infections in Finland in 1976-1987. Scand. J. Infect. Dis. 21:1989;527.
31. Runeberg-Nyman K., Butcher S., Wahlström E., Muttilainen S., Nurminen M., Sarvas M. Neisseria meningitidis major outermembrane protein P1: structure prediction and tentative identification of protective epitopes. Chanock R.M., Ginsberg H.S., Brown F., Lerner R.L., Vaccines 91. 1991;415 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
32. Holten E. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J. Clin. Microbiol. 9:1979;186.
33. McGuinness B., Barlow A.K., Clarke I.N., Farley J.E., Anilionis A., Poolman J.T., Heckels J.E. Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis: synthetic peptides define the epitopes responsible for serosubtype specificity. J. Exp. Med. 171:1990;1871.
34. Høiby E.A., Rosenqvist E., Frøholm L.O., Bjune G., Feiring B., Nøkleby H., Rønnild E. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH An. 14:1991;147.
35. Aase A., Michaelsen T.E. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand. J. Immunol. 39:1994;581.
36. Frosch M., Görgen I., Boulnois G.J., Timmis K.N., Bitter-Suermann D. NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc. Natl. Acad. Sci. 82:1985;1194.
37. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Frøholm L.O., Lindbak A.-K., Møgster B., Namork E., Rye U., Stabbetorp G., Winsnes R., Aase B., Closs O. Production, characterization and control of MenB-vaccine 'Folkehelsa': an outer membrane vesicle vaccine against group B meningococcal disease. NIPH An. 14:1991;67.
38. Wedege E., Frøholm L.O. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun. 51:1986;571.
39. Wedege E., Bryn K., Frøholm L.O. Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J. Immunol. Methods. 113:1988;51.
40. Wedege E., Høiby E.A., Rosenqvist E., Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66:1998;3223.
41. Brodeur B.R., Larose Y., Tsang P., Hamel J., Ashton F., Ryan A. Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody. Infect. Immun. 50:1985;510.
42. Infante J.F., Marrero O., Sifontes S., Sierra G., Campa C., Caro E., Gutierrez M., Malberti A., Capo V., Fariñas M., Muñoz E. Evaluation of the efficacy of human antimeningococcal immunoglobulin G in infant rats experimentally infected with Neisseria meningitidis group B. Arch. Med. Res. 25:1994;455.
43. Smith A.L., Smith D.H., Averill D.R., Marino J., Moxon E.R. Production of Haemophilus influenzae b meningitis in infant rats by intraperitoneal inoculation. Infect. Immun. 8:1973;278.
44. Poolman J.T., Lind I., Jónsdóttir K., Frøholm L.O., Jones D.M., Zanen H.C. Meningococcal serotypes and serogroup B disease in North-West Europe. Lancet. ii:1986;555.
45. Frasch C.E., Parkes L., McNelis R.M., Gotschlich E.C. Protection against group B meningococcal disease I. Comparison of group-specific and type-specific protection in the chick embryo model. J. Exp. Med. 144:1976;319.